Centogene N.V. (CNTG)
| Market Cap | 226.47M |
| Revenue (ttm) | 156.56M |
| Net Income (ttm) | -26.20M |
| Shares Out | 22.45M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,908 |
| Open | 10.19 |
| Previous Close | 10.29 |
| Day's Range | 9.93 - 10.30 |
| 52-Week Range | 8.61 - 14.79 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.84 (+106.5%) |
| Est. Earnings Date | Dec 9, 2021 |
About CNTG
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including tar...
Financial Performance
In 2020, Centogene's revenue was 128.38 million, an increase of 163.18% compared to the previous year's 48.78 million. Losses were -21.49 million, 4.01% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Centogene stock is "Strong Buy." The 12-month stock price forecast is 20.84, which is an increase of 106.50% from the latest price.
News
New Strong Sell Stocks for September 10th
CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021
Centogene N.V. (CNTG) Reports Q2 Loss, Tops Revenue Estimates
Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021.
CENTOGENE Reports Second Quarter 2021 Financial Results
Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank Strong Revenues and Steady Return to Core Business Growt...
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare D...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event Highlights strategic priorities to lead data-driven insights creation for rare disea...
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
Further signs of recovery in the core rare disease business Further signs of recovery in the core rare disease business
Centogene N.V. (CNTG) Stock Jumps 7.5%: Will It Continue to Soar?
Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average.
CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Announces Virtual Investor Event
New leadership team to present vision, strategy, and execution roadmap New leadership team to present vision, strategy, and execution roadmap
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...
CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, under...
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical ...
CENTOGENE Extends Global Parkinson's Disease Study
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson's disease (PD)
Centogene (CNTG) Enters Oversold Territory
Centogene (CNTG) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
CENTOGENE's rare disease mutation database offers new features and previously unpublished variants CENTOGENE's rare disease mutation database offers new features and previously unpublished variants
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
Research leads to diagnosis and treatment options for rare disease patients Research leads to diagnosis and treatment options for rare disease patients
CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results
Delivers very strong financial results in unprecedented year Delivers very strong financial results in unprecedented year
CENTOGENE Extends Partnership With Takeda
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical a...
CENTOGENE to Announce Full Year 2020 Financial Results on April 15, 2021
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...
CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson's Disease Study
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinica...